BR112013024809A2 - tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas - Google Patents
tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadasInfo
- Publication number
- BR112013024809A2 BR112013024809A2 BR112013024809A BR112013024809A BR112013024809A2 BR 112013024809 A2 BR112013024809 A2 BR 112013024809A2 BR 112013024809 A BR112013024809 A BR 112013024809A BR 112013024809 A BR112013024809 A BR 112013024809A BR 112013024809 A2 BR112013024809 A2 BR 112013024809A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- treatment
- combination
- virus
- liver diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas a invenção refere-se ao uso de inibidores de ciclofilina (tais como alisporivir ou deb025) no tratamento de hepatite b e infecção por vírus de hepatite d, opcionalmente em combinação com interferona e telbivudina, lamivudina, emtricibina, entecavir, adefovir ou tenofovir.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470666P | 2011-04-01 | 2011-04-01 | |
PCT/EP2012/055857 WO2012131061A1 (en) | 2011-04-01 | 2012-03-30 | Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013024809A2 true BR112013024809A2 (pt) | 2016-09-06 |
Family
ID=45952512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013024809A BR112013024809A2 (pt) | 2011-04-01 | 2012-03-30 | tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas |
Country Status (22)
Country | Link |
---|---|
US (3) | US20140011736A1 (pt) |
EP (2) | EP2694087B1 (pt) |
JP (1) | JP2014509630A (pt) |
KR (1) | KR20140010097A (pt) |
CN (1) | CN103458913A (pt) |
AU (2) | AU2012237295A1 (pt) |
BR (1) | BR112013024809A2 (pt) |
CA (1) | CA2831675A1 (pt) |
CY (1) | CY1116374T1 (pt) |
DK (1) | DK2694087T3 (pt) |
ES (1) | ES2533213T3 (pt) |
HK (1) | HK1193571A1 (pt) |
HR (1) | HRP20150430T1 (pt) |
MX (1) | MX2013011411A (pt) |
PL (1) | PL2694087T3 (pt) |
PT (1) | PT2694087E (pt) |
RS (1) | RS53911B1 (pt) |
RU (1) | RU2013148779A (pt) |
SI (1) | SI2694087T1 (pt) |
SM (1) | SMT201500132B (pt) |
TW (1) | TW201247216A (pt) |
WO (1) | WO2012131061A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120208746A1 (en) * | 2011-01-12 | 2012-08-16 | Scynexis Inc. | Genetic markers associated with response to cyclophilin-binding compounds |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
WO2016090107A2 (en) * | 2014-12-04 | 2016-06-09 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
CN107530338B (zh) | 2015-04-21 | 2020-12-01 | 艾格尔峰生物制药有限公司 | 包含洛那法尼和利托那韦的药物组合物 |
RU2662161C1 (ru) * | 2017-08-11 | 2018-07-24 | Васильевич Иващенко Александр | Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита |
JP2021534218A (ja) * | 2018-08-23 | 2021-12-09 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドEiger Biopharmaceuticals, Inc. | インターフェロンラムダでのデルタ肝炎ウイルス感染処置 |
US20220313690A1 (en) * | 2019-07-18 | 2022-10-06 | Enyo Pharma | Synergistic effect of eyp001 and ifn for the treatment of hbv infection |
CN114945361A (zh) * | 2020-01-15 | 2022-08-26 | 法国国家卫生及研究医学协会 | Fxr激动剂在治疗丁型肝炎病毒感染中的用途 |
CN113662945A (zh) * | 2020-05-15 | 2021-11-19 | 福建广生堂药业股份有限公司 | 用于治疗乙型肝炎的组合 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
EP0251575B2 (en) * | 1986-06-17 | 2002-11-13 | Chiron Corporation | Hepatitis delta diagnostics and vaccines, their preparation and use |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
ES2174915T3 (es) | 1993-11-10 | 2002-11-16 | Enzon Inc | Productos de conjugacion mejorados de un interferon con un polimero. |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
DK1793844T3 (da) * | 2004-10-01 | 2011-03-21 | Debiopharm Sa | Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion |
AU2005322242B2 (en) | 2004-12-23 | 2010-02-11 | Novartis Ag | Compositions for HCV treatment |
-
2012
- 2012-03-30 JP JP2014501660A patent/JP2014509630A/ja active Pending
- 2012-03-30 KR KR1020137025396A patent/KR20140010097A/ko not_active Application Discontinuation
- 2012-03-30 CA CA2831675A patent/CA2831675A1/en not_active Abandoned
- 2012-03-30 AU AU2012237295A patent/AU2012237295A1/en not_active Abandoned
- 2012-03-30 TW TW101111555A patent/TW201247216A/zh unknown
- 2012-03-30 BR BR112013024809A patent/BR112013024809A2/pt not_active IP Right Cessation
- 2012-03-30 ES ES12713680.2T patent/ES2533213T3/es active Active
- 2012-03-30 PL PL12713680T patent/PL2694087T3/pl unknown
- 2012-03-30 MX MX2013011411A patent/MX2013011411A/es not_active Application Discontinuation
- 2012-03-30 US US14/007,468 patent/US20140011736A1/en not_active Abandoned
- 2012-03-30 EP EP12713680.2A patent/EP2694087B1/en active Active
- 2012-03-30 PT PT127136802T patent/PT2694087E/pt unknown
- 2012-03-30 DK DK12713680T patent/DK2694087T3/en active
- 2012-03-30 RS RS20150233A patent/RS53911B1/en unknown
- 2012-03-30 SI SI201230181T patent/SI2694087T1/sl unknown
- 2012-03-30 RU RU2013148779/15A patent/RU2013148779A/ru not_active Application Discontinuation
- 2012-03-30 EP EP15190917.3A patent/EP3006037A1/en not_active Withdrawn
- 2012-03-30 CN CN2012800172986A patent/CN103458913A/zh active Pending
- 2012-03-30 WO PCT/EP2012/055857 patent/WO2012131061A1/en active Application Filing
-
2014
- 2014-07-10 HK HK14107028.5A patent/HK1193571A1/xx not_active IP Right Cessation
- 2014-07-28 US US14/444,418 patent/US20150023917A1/en not_active Abandoned
-
2015
- 2015-04-20 HR HRP20150430TT patent/HRP20150430T1/hr unknown
- 2015-04-24 CY CY20151100380T patent/CY1116374T1/el unknown
- 2015-06-10 SM SM201500132T patent/SMT201500132B/xx unknown
- 2015-10-07 US US14/877,241 patent/US20160101146A1/en not_active Abandoned
-
2016
- 2016-03-24 AU AU2016201888A patent/AU2016201888A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN103458913A (zh) | 2013-12-18 |
HK1193571A1 (en) | 2014-09-26 |
EP3006037A1 (en) | 2016-04-13 |
RU2013148779A (ru) | 2015-05-10 |
US20160101146A1 (en) | 2016-04-14 |
EP2694087B1 (en) | 2015-01-28 |
ES2533213T3 (es) | 2015-04-08 |
AU2016201888A1 (en) | 2016-04-21 |
US20140011736A1 (en) | 2014-01-09 |
MX2013011411A (es) | 2014-04-14 |
HRP20150430T1 (hr) | 2015-05-22 |
PT2694087E (pt) | 2015-04-09 |
WO2012131061A1 (en) | 2012-10-04 |
RS53911B1 (en) | 2015-08-31 |
PL2694087T3 (pl) | 2015-06-30 |
CY1116374T1 (el) | 2017-02-08 |
SI2694087T1 (sl) | 2015-05-29 |
AU2012237295A1 (en) | 2013-09-19 |
KR20140010097A (ko) | 2014-01-23 |
SMT201500132B (it) | 2015-07-09 |
EP2694087A1 (en) | 2014-02-12 |
US20150023917A1 (en) | 2015-01-22 |
DK2694087T3 (en) | 2015-04-13 |
JP2014509630A (ja) | 2014-04-21 |
TW201247216A (en) | 2012-12-01 |
CA2831675A1 (en) | 2012-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013024809A2 (pt) | tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas | |
CY1123324T1 (el) | Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων | |
BR112014018918A8 (pt) | Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais | |
MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
PH12018550207A1 (en) | Phosphoramidates for the treatment of hepatitis b virus | |
PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
EA201490208A1 (ru) | Тенофовир алафенамида гемифумарат | |
PH12014501314A1 (en) | Hepatitis b antiviral agents | |
PH12015502780B1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
EA201490947A1 (ru) | Производные пурина для лечения вирусных инфекций | |
PH12015500073A1 (en) | Macrocyclic purines for the treatment of viral infections | |
BR112014007852A2 (pt) | nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos | |
EA201290993A1 (ru) | Нуклеозидфосфорамидаты | |
BRPI1007476A2 (pt) | análogos de ciclosporina para prevenir ou tratar infecção por hepatite c | |
BR112014008616A2 (pt) | compostos antivirais | |
EA201790786A1 (ru) | Комбинированная терапия вызываемой вирусами hbv и hdv инфекции | |
MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
TN2013000397A1 (en) | Treatment of hepatitis c virus infection with alisporivir | |
MY178600A (en) | Antiviral composition against chikungunya virus | |
TH129939B (th) | องค์ประกอบสำหรับรักษาตับอักเสบบีเรื้อรังซึ่งมีคลีวูดีน (clevudine) และแอดีโฟเวียร์ไดไพวอกซิล (adefovir dipivoxil) | |
CR20150060A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |